Predicting RLT Resistance with Metabolomics and Imaging in Mice
Radioligand therapy (RLT) has emerged as a transformative precision oncology approach with remarkable initial response rates. However, treatment resistance remains a critical challenge that can limit long-term therapeutic success. Imaging technologies—including PET,...
Using Metabolomics and Imaging to Track RLT Response
Radioligand therapy (RLT) represents a paradigm shift in precision oncology, delivering targeted radiation directly to cancer cells while minimizing damage to healthy tissue. Cell line-derived xenograft (CDX) models serve as essential platforms for RLT development,...
Decoding RLT Resistance with Multi‑Omics Profiling
One of the most challenging aspects of radioligand therapy (RLT) development is understanding why initially responsive tumors eventually develop resistance to treatment. While imaging can show when treatments stop working, it cannot reveal the underlying molecular...